Loading...
EAR logo

Eargo, Inc.NasdaqGS:EAR 株式レポート

時価総額 US$53.4m
株価
n/a
私の公正価値
n/a
1Y-64.3%
7D-2.7%
ポートフォリオ価値
​
表示

Eargo, Inc.

NasdaqGS:EAR 株式レポート

時価総額：US$53.4m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Eargo（EAR）株式概要

Eargo, Inc., a medical device company, engages in enhancing the quality of life of people with hearing loss in the United States. 詳細

EAR ファンダメンタル分析
スノーフレーク・スコア
評価2/6
将来の成長0/6
過去の実績0/6
財務の健全性4/6
配当金0/6

リスク分析

過去5年間で収益は年間35.8%減少しました。

キャッシュランウェイが1年未満である

意味のある時価総額がありません ( $53M )


EAR Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Eargo, Inc. 競合他社

価格と性能

株価の高値、安値、推移の概要Eargo
過去の株価
現在の株価US$2.57
52週高値US$7.52
52週安値US$1.47
ベータ1.48
1ヶ月の変化-3.75%
3ヶ月変化0.62%
1年変化-64.31%
3年間の変化-99.80%
5年間の変化n/a
IPOからの変化-99.62%

最新ニュース

Recent updates

Seeking Alpha • Aug 30

Eargo: Straining To Be Heard

Summary Today, we take our first look at a small medical device company called Eargo, Inc. whose stock has slumped 90% over the past year. A good portion of the decline was caused by two key issues, both of which company management is hoping to put in the rearview mirror. An investment analysis follows in the paragraphs below. The art of conversation is the art of hearing as well as of being heard."― William Hazlitt Today, we put Eargo, Inc.(EAR) in the spotlight for the first time. This company has a variety of issues recently that have caused the stock to nosedive deep into 'Busted IPO' territory. Are brighter times on the horizon? An analysis follows below. Seeking Alpha Company Overview: Eargo, Inc. is a small medical device maker headquartered in San Jose, CA. The company markets and sells hearing aids through direct-to-consumer and through omni-channels. The stock currently has an approximate market capitalization of $75 million. The company launched the latest version of its hearing aid line, the Eargo 6 in January of this year. The Eargo 6 is an FDA Class II exempt hearing device featuring Sound Adjust technology that automatically optimizes the soundscape as the user moves between environments. June Company Presentation The company has been dogged by two major issues since it went public. The first was a criminal investigation initiated by the U.S. Department of Justice related to insurance reimbursement claims submitted by the company on behalf of its customers covered by the Federal Employee Health Benefits (FEHB) program. Management denied wrongdoing but settled this issue for $34.4 million in the Spring of this year. June Company Presentation Eargo also no longer accepted insurance as a method of direct payment in late 2021. In the second quarter of this year, Eargo operated on a cash-pay only basis which tanked sales (see section below). The company did get some very good news on this front two weeks ago as the FDA disclosed it would allow the sale of some hearing aids over the counter beginning in October. June Company Presentation The company has shipped over 110,000 hearing aid devices in its history and believes the market is significantly underpenetrated especially for its in-ear devices that offer several advantages to traditional hearing aids. June Company Presentation Second Quarter Results: On August 8th, the company posted second quarter numbers. The company had a GAAP loss of 78 cents a share as revenues plunged nearly 70% on a year-over-year basis to $7.25 million. Both top and bottom lines missed expectations badly. Returns rose to a third of sales from just less than a quarter in the same period a year ago. GAAP gross margin was 34.7%, compared to 71.8% in 2Q2021. Management stated via its earnings press release, the company would be focused on four key areas going forward. Eargo's omni-channel growth strategy Potentially regaining insurance coverage of Eargo for government employees under the FEHB program Refining and expanding the company's physical retail strategy Optimize the cash-pay business while continuing to invest in innovation. June Company Presentation Analyst Commentary & Balance Sheet: Wells Fargo ($10 price target), JPMorgan ($11 price target) and William Blair either maintained or downgraded Eargo to a Hold in the fourth quarter of 2021, but no analyst firms I can find have issued any ratings on Eargo so far in 2022. Just over one out of every ten shares are currently held short. Two insiders sold just over $40,000 in aggregate earlier this month. Another insider sold less than $15,000 worth of equity in March. That has been the only insider activity in Eargo's shares so far in 2022. The company ended the second quarter of the year with just over $106 million in cash and marketable securities on its balance sheet. This is almost entirely due to an issuance of $100 million senior secured convertible notes that occurred late in June. This is the core tranche of a $125 million strategic investment from Patient Square Capital. $16.2 million of these proceeds were used to pay off a previous debt obligation. Management will seek stockholder approval to increase the number of authorized shares and issue full potential amount of note conversion shares at its annual meeting in October of this year. If approved, this will consist of new shares of common stock created by a rights offering.
Seeking Alpha • Aug 16

Eargo jumps 77% following FDA rule on OTC hearing aids

Microcap Eargo (NASDAQ:EAR) closed up 77% on Tuesday following the U.S. FDA's announcement that it would allow the sale of some hearing aids over the counter beginning in October. Average daily volume for the company is ~4.2M shares. ~31.8M shares traded hands on Tuesday. Seeking Alpha's Quant Rating views Eargo (EAR) as a strong sell.
Seeking Alpha • Aug 08

Eargo Non-GAAP EPS of -$0.78 misses by $0.55, revenue of $7.25M misses by $21.05M

Eargo press release (NASDAQ:EAR): Q2 Non-GAAP EPS of -$0.78 misses by $0.55. Revenue of $7.25M (-68.3% Y/Y) misses by $21.05M.
Seeking Alpha • Jul 05

Eargo completes $100M senior secured convertible notes issuance

Medical device company Eargo (NASDAQ:EAR) completed the issuance of $100M senior secured convertible notes to Patient Square Capital on Jun. 28. ~$16.3M of the net proceeds was used to repay all existing third-party indebtedness and related pay-off expenses. The remaining proceeds are intended to be used for working capital purposes and to fund general business requirements. Source: Press Release
Seeking Alpha • Dec 30

Eargo: A Binary Play On Hearing Loss

Eargo has exhibited stupendous sales growth in recent years and that looks set to continue. But this growth comes at the cost of significant cash outflows that have largely increased over time. The company's value is implied to be very small at this time, which could lead to significant upside if things go right. But significant risks definitely exist, making the company a binary prospect currently.
Seeking Alpha • Oct 08

Eargo Is A High Risk 'Option' With High Potential

Eargo Inc. is a US-based small-cap public company that manufactures and distributes Completely-In-Canal (CIC) hearing aids throughout the country. The company will be one of the beneficiaries of promoting sales of OTC hearing aids in the United States. Eargo Inc. has created a highly competitive product that meets high-quality standards at an affordable price.
分析記事 • Jul 10

An Intrinsic Calculation For Eargo, Inc. (NASDAQ:EAR) Suggests It's 23% Undervalued

In this article we are going to estimate the intrinsic value of Eargo, Inc. ( NASDAQ:EAR ) by estimating the company's...
分析記事 • Jan 16

What Kind Of Investors Own Most Of Eargo, Inc. (NASDAQ:EAR)?

If you want to know who really controls Eargo, Inc. ( NASDAQ:EAR ), then you'll have to look at the makeup of its share...

株主還元

EARUS Medical EquipmentUS 市場
7D-2.7%4.0%-0.3%
1Y-64.3%-18.6%26.7%

業界別リターン: EAR過去 1 年間で-18.6 % の収益を上げたUS Medical Equipment業界を下回りました。

リターン対市場: EARは、過去 1 年間で26.7 % のリターンを上げたUS市場を下回りました。

価格変動

Is EAR's price volatile compared to industry and market?
EAR volatility
EAR Average Weekly Movement2.7%
Medical Equipment Industry Average Movement8.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.2%

安定した株価: EAR 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。

時間の経過による変動: EARの 週次ボラティリティ は、過去 1 年間で11%から3%に減少しました。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
2010243Bill Brownieeargo.com

Eargo, Inc. 基礎のまとめ

Eargo の収益と売上を時価総額と比較するとどうか。
EAR 基礎統計学
時価総額US$53.39m
収益（TTM）-US$108.17m
売上高(TTM)US$41.11m
1.3x
P/Sレシオ
-0.5x
PER（株価収益率

EAR は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
EAR 損益計算書（TTM）
収益US$41.11m
売上原価US$23.86m
売上総利益US$17.25m
その他の費用US$125.42m
収益-US$108.17m

直近の収益報告

Sep 30, 2023

次回決算日

該当なし

一株当たり利益（EPS）-5.21
グロス・マージン41.95%
純利益率-263.14%
有利子負債／自己資本比率0%

EAR の長期的なパフォーマンスは？

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2024/02/20 20:50
終値2024/02/20 00:00
収益2023/09/30
年間収益2022/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Eargo, Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4

アナリスト機関
Robert HopkinsBofA Global Research
Robert MarcusJ.P. Morgan
Lawrence BiegelsenWells Fargo Securities, LLC